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Abstract
The 22q11.2 deletion (22q11DS) is a common chromosomal microdeletion and a potent risk factor for psychotic illness.
Prior studies reported widespread cortical changes in 22q11DS, but were generally underpowered to characterize
neuroanatomic abnormalities associated with psychosis in 22q11DS, and/or neuroanatomic effects of variability in deletion
size. To address these issues, we developed the ENIGMA (Enhancing Neuro Imaging Genetics Through Meta-Analysis)
22q11.2 Working Group, representing the largest analysis of brain structural alterations in 22q11DS to date. The imaging
data were collected from 10 centers worldwide, including 474 subjects with 22q11DS (age= 18.2 ± 8.6; 46.9% female) and
315 typically developing, matched controls (age= 18.0 ± 9.2; 45.9% female). Compared to controls, 22q11DS individuals
showed thicker cortical gray matter overall (left/right hemispheres: Cohen’s d= 0.61/0.65), but focal thickness reduction in
temporal and cingulate cortex. Cortical surface area (SA), however, showed pervasive reductions in 22q11DS (left/right
hemispheres: d=−1.01/−1.02). 22q11DS cases vs. controls were classiﬁed with 93.8% accuracy based on these
neuroanatomic patterns. Comparison of 22q11DS-psychosis to idiopathic schizophrenia (ENIGMA-Schizophrenia Working
Group) revealed signiﬁcant convergence of affected brain regions, particularly in fronto-temporal cortex. Finally, cortical SA
was signiﬁcantly greater in 22q11DS cases with smaller 1.5 Mb deletions, relative to those with typical 3 Mb deletions. We
found a robust neuroanatomic signature of 22q11DS, and the ﬁrst evidence that deletion size impacts brain structure.
Psychotic illness in this highly penetrant deletion was associated with similar neuroanatomic abnormalities to idiopathic
schizophrenia. These consistent cross-site ﬁndings highlight the homogeneity of this single genetic etiology, and support the
suitability of 22q11DS as a biological model of schizophrenia.
Introduction
Micro-deletions or duplications of chromosomal regions
(copy number variants; CNVs) are causally involved in a
range of developmental brain disorders [1]. One such
recurrent CNV is a deletion in the 22q11.2 region, typically
encompassing ~50 protein-coding genes [2], which causes
the 22q11.2 deletion syndrome (22q11DS; OMIM
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#188400, #192430). 22q11DS is one of the most penetrant
genetic risk factors for psychotic illness [3], increasing risk
around 30-fold relative to the general population [4–6].
22q11DS is also associated with varied phenotypic
expression, including cardiac defects, craniofacial anoma-
lies, and intellectual disability [2, 7]. Given its known,
relatively homogeneous genetic etiology, investigation of
this microdeletion offers a unique opportunity to identify
early neural biomarkers of psychosis.
Neuroanatomic alterations in 22q11DS have been
investigated in several single-site studies. Early magnetic
resonance imaging (MRI) studies reported whole-brain
volumetric reductions in 22q11DS, particularly in midline
cortical regions [8–11]. A rostro-caudal gradient of volu-
metric reduction was also reported, with greatest reduction
in occipital lobes, while frontal regions were relatively
preserved [12]. More recent studies have parcellated the
cerebral cortex in detail, investigating measures of cortical
thickness and surface area [13, 14], which may have distinct
genetic and neurobiological origins [15, 16]. Some studies
noted increases in cortical thickness in 22q11DS relative to
controls, with focal thinning in the superior temporal gyrus
and cingulate cortex, along with global reductions in surface
area [8, 13, 14, 17–19]. It is not clear, however, if these
patterns are universally found in 22q11DS. Moreover, in
other neurogenetic conditions larger deletions are associated
with greater phenotypic severity [20]; yet, to our knowl-
edge, no prior studies have investigated the neuroanatomic
effects of variations in 22q11.2 deletion size.
Determining the neural substrates of psychotic illness in
22q11DS has been a major focus of investigation. Meta-
analyses of structural MRI studies of patients with idio-
pathic schizophrenia report lower volumes in frontal and
temporal regions [21–24], including the anterior cingulate
and insula [25, 26]. Some evidence suggests that neuroa-
natomic regions typically disrupted in idiopathic schizo-
phrenia are also linked to psychosis in 22q11DS. Lower
frontal and superior temporal gyrus (STG) gray matter
volumes were observed in adults with 22q11DS and a
schizophrenia diagnosis, relative to 22q11DS adults without
schizophrenia [19, 27, 28]. Kates et al. [29] also found that
progressive volumetric decreases in STG predicted later
psychotic symptoms in 22q11DS youth, and lower cingu-
late gyrus volume was associated with more severe psy-
chotic symptoms [30]. These initial studies support overlap
between neuroanatomic abnormalities in idiopathic schizo-
phrenia and 22q11DS-associated psychosis; however, con-
ﬁrmation in a large-scale study and systematic comparison
of regional changes between psychosis in 22q11DS and
idiopathic schizophrenia are needed.
To address these questions, researchers worldwide
studying cohorts of 22q11.2 deletion carriers formed the
22q11.2 Working Group as part of the Enhancing
NeuroImaging Genetics through Meta-Analysis (ENIGMA)
Consortium [31–33] (http://enigma.ini.usc.edu). With the
goal of data harmonization across sites, this consortium
effort represents the largest-ever analysis of brain structural
alterations in 22q11DS. We addressed the following
research questions:
1. Is there a distinct neuroanatomic signature of
22q11DS?
2. Do cortical metrics differ between 22q11DS indivi-
duals with and without psychosis? Do these neuroa-
natomic patterns overlap with those of idiopathic
schizophrenia?
3. Does the size of the 22q11.2 deletion affect the
magnitude of cortical alterations?
Methods
Participants
Seven-hundred and eighty-nine individuals – 474 22q11DS
subjects and 315 typically developing controls - from
10 study sites in the ENIGMA 22q11DS working group
were included in the analyses. These individuals were
selected from a larger pool of 944 participants, after
excluding related individuals (N= 79) and individuals with
poor quality MRI scans (N= 65) or extreme brain measures
(N= 11). Study inclusion/exclusion criteria and measures
are detailed for each sample in Supplementary Table S1.
Institutional review boards at participating institutions
approved all study procedures. Written informed consent/
assent was obtained from all study participants.
Image acquisition
Thirteen sets of T1-weighted MRI anatomical brain scans
were acquired from 10 participating sites; acquisition
parameters are detailed in Supplementary Table S2. The
imaging data from UCLA, UC Davis and University of
Toronto were each acquired on two different scanners, and
were therefore treated as independent data sets in the
analyses.
Image processing
De-identiﬁed scans from each site were transferred to secure
UCLA servers; image processing and analyses were con-
ducted on secure USC Laboratory of Neuro Imaging
(LONI) servers. Scans were processed using FreeSurfer
(version 5.3.0) [34]. Quality control was performed for each
scan, including visual inspection and the use of standardized
ENIGMA quality control procedures (http://enigma.ini.usc.
D. Sun et al.
edu/protocols/imaging-protocols) [35, 36]. Applying Free-
Surfer’s reconstruction pipeline, local cortical thickness
(CT) and surface area (SA) were calculated on each vertex
of reconstructed hemispheric surface model [37], and sta-
tistical analyses were conducted on each vertex. Measures
of CT and SA were also obtained from 68 cortical regions
(34 per hemisphere), based on the Desikan–Killiany atlas
[38], and these regional measures were used to identify
appropriate modeling for the above-mentioned surface-
based analyses (see Supplementary Methods for details).
Statistical analyses
22q11DS vs. control differences
This comparison included 701 individuals (22q11DS n=
386; control n= 315) from 11 data sets involving 9 study
sites; subjects from 2 sites (Toronto and Utrecht) that had
no healthy control data were excluded from this analysis.
Group differences in CT and SA were examined using
general linear models (GLM), with each brain measure as
the dependent variable and group as the independent vari-
able, adjusted for data set/site, sex, and age. Based on data
visualization and model comparisons (Supplementary Fig-
ure S1a,b; Supplementary Tables S3a,b), age effects were
modeled linearly for SA, while a quadratic term was
included in the model for CT. Interactions between group,
sex, and age were largely non-signiﬁcant (Supplementary
Tables S4a,b; S5a,b) and therefore not included in the
models. Because intracranial volume (ICV) was sig-
niﬁcantly correlated with global SA but not CT (Supple-
mentary Figure S2), ICV was included as a covariate only
for SA comparisons, in all analyses. Treating data set as a
random variable, mixed linear models were also used for
comparison (see Supplemental Methods). Cohen’s d effect
size estimates were derived from t-values for the group
differences [39]. For all signiﬁcance tests, the False Dis-
covery Rate (FDR) [40] with q-value at 0.05 was applied to
control false positive errors due to multiple comparisons.
FDR-corrected p-values below 0.05 were considered sig-
niﬁcant. All surface-based analyses were conducted using
FreeSurfer’s mri_glmﬁt. Tests for individual cortical regions
were performed in the R statistical environment [41].
22q11DS vs. control classiﬁcation analysis
To examine how accurately 22q11DS subjects can be dif-
ferentiated from controls based on cortical measures, a
machine-learning based classiﬁcation analysis was con-
ducted on the regional CT and SA values from the same
data sets described above using Glmnet. Glmnet uses an L1-
norm regularization to ﬁt a generalized linear model. It
implements built-in feature selection, and is robust when
predictors are highly correlated [42]. The Caret package
[43] in R was used to facilitate training and testing. Spe-
ciﬁcally, the whole data set was randomly divided into
training sets and testing sets 20 times at a ratio of 3:1. For
each division, 10-fold cross-validations were conducted on
the training set to achieve an optimized model, which was
then applied to testing data to evaluate classiﬁcation accu-
racy. Sensitivity, speciﬁcity, and accuracy of group pre-
diction were averaged over the 20 divisions.
To further test the reliability of prediction, brain scans
from the two sites with only 22q11DS cases (n= 88) were
used as an independent validation data set, to which the
model trained from the above-mentioned data was applied.
Effects of psychosis on brain structure
To compare cortical measures between 22q11DS subjects
with (22q11DS+ Psychosis) and without psychosis
(22q11DS-No-Psychosis), each 22q11DS+ Psychosis sub-
ject was matched to a 22q11DS-No-Psychosis subject at the
same site, with the same sex, and closest age. Psychosis
diagnosis was determined by structured clinical interview at
each site; for a subset, diagnoses were validated across sites
via a consensus procedure [44] (see Supplementary Meth-
ods, Table S1). Group comparisons were conducted using
GLM controlling for site, sex, and age. No group x age
interactions were signiﬁcant, and thus were not included in
statistical models. Based on statistical model comparisons,
age was treated as a linear term for both CT and SA
(Supplementary Tables S6a,b). As in the above analyses,
ICV was adjusted for SA comparisons. Secondly, we con-
ducted a classiﬁcation analysis using the same
Glmnet algorithm described above, in order to determine
whether we could accurately distinguish 22q11DS cases
with psychosis from those without, based on neuroanatomic
patterns.
Pattern similarity in cortical measures between 22q11DS
with psychosis and idiopathic schizophrenia
To further clarify if psychosis-related brain alterations in
22q11DS resemble the pattern observed in idiopathic schi-
zophrenia, we correlated the effect sizes (Cohen’s d) for
cortical measures from the comparison of psychotic vs. non-
psychotic 22q11DS subjects with those from the ENIGMA
schizophrenia working group, the largest meta-analysis of
structural brain alterations in schizophrenia (4474 patients
with idiopathic schizophrenia; 5098 healthy controls) [45].
To investigate the speciﬁcity of the above correlation, a
parallel analysis was conducted for psychotic vs. non-
psychotic 22q11DS compared to major depressive disorder
(MDD; N= 1902) vs. healthy controls (N= 7658) from the
ENIGMA MDD Working Group [35].
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Proximal nested (A–B) vs typical (A–D) 22q11.2 deletions
The combined data sets of 22q11DS subjects included
microdeletions of variable size; the large sample size
allowed comparison of anatomical effects of the two most
frequent 22q11.2 deletion types, the typical ~3 Megabase
(Mb) A–D deletion (present in ~85% of cases) and the
smaller, nested ~1.5 Mb A–B deletion (present in ~10% of
cases) [2]. Deletion size was determined using multiplex
ligation-dependent probe ampliﬁcation (MLPA) [46]. Each
subject with an A–B deletion was matched with
4–5 subjects with A–D deletions, and 4–5 healthy controls,
based on same site and sex, and closest age. The three
groups were compared in an analysis of covariance
(ANCOVA) model, controlling for site, sex, and age, with
post-hoc pairwise contrasts between each group. Age2 [2]
was modeled for CT, as signiﬁcant quadratic age effects
were observed; however, age was modeled linearly for SA,
as no signiﬁcant nonlinear effects were observed (Supple-
mentary Tables S7a,b). Again, ICV was covaried in SA
comparisons.
Medication, Handedness and IQ Effects
Secondary analyses addressed effects of medication usage,
handedness and IQ on cortical structure (Supplementary
Methods, Table S8).
Results
22q11DS vs. control differences
There were no differences in sex or age between 22q11DS
subjects and controls, either within each site, or when all
sites were combined (Table 1). However, a greater pro-
portion of controls were right-handed and, as expected,
controls had signiﬁcantly higher IQ than 22q11DS cases.
As such, these variables were examined in secondary ana-
lyses, as noted above.
Overall brain metrics were highly consistent across sites
(Supplementary Figure S3 and Table S9). We found wide-
spread reductions in SA, along with globally thicker cortical
gray matter in 22q11DS subjects relative to controls. The
spatial pattern of thicker cortex in 22q11DS resembled that
of SA reduction, with the exception of thicker cortex in
bilateral insula, and thinner cortex relative to controls in
bilateral parahippocampal and superior temporal gyri, and
left caudal anterior cingulate cortex (Fig. 1a). The most
prominent SA reductions were found bilaterally in the
medial occipital and anterior cingulate cortex; superior par-
ietal cortex and rostral middle frontal gyrus were among the
lateral regions showing signiﬁcantly smaller SA in 22q11DS
vs. controls (Fig. 1b). Effect sizes and p-values of regional
CT and SA differences are shown in Supplementary
Tables S10a,b, respectively, indicating that effect sizes for
reduced SA in 22q11DS vs. controls were roughly twice the
size of the effects for increased CT. Scatterplots displaying
these results are in Supplementary Figures S4a,b. The
overall pattern of ﬁndings remained the same when mixed-
effects models were used [Supplementary Table S11a,b].
22q11DS vs. control classiﬁcation
An average classiﬁcation accuracy of 93.8% (p= 4.46 ×
10−26, sensitivity 94.2%; speciﬁcity 93.3%) was achieved
across 20 runs (Supplementary Table S12a). The top ﬁve
contributors to the overall accuracy of the model were SA in
the left caudal anterior cingulate, precentral gyrus, and
bilateral cuneus, and CT in the left insula (Supplementary
Table S12b). When the classiﬁer derived from the 11 data
sets with cases and controls was applied to the 2 data sets
with only 22q11DS cases, a classiﬁcation sensitivity of
100% was achieved (i.e., all were classiﬁed as cases).
Effects of psychosis on brain structure
The matched groups of 22q11DS+ Psychosis (n= 60) and
22q11DS-No-Psychosis (n= 60) were similar in demo-
graphic characteristics, although those with psychosis had
signiﬁcantly lower IQ and increased proportion of anti-
psychotic medication usage, as expected (Supplementary
Table S13a,b).
Relative to the 22q11DS-No-Psychosis group, the
22q11DS+ Psychosis group showed signiﬁcantly thinner
cortex in the left superior temporal gyrus and lateral occipital
cortex, and right medial superior frontal, cingulate, pre- and
post-central, and supramarginal gyri (Fig. 2). No signiﬁcant
differences in SA were found between 22q11DS subjects
with and without psychosis. Effect sizes and p-values for
cortical regions are presented in Supplementary Table S14a,
b, which showed signiﬁcant CT differences across several
frontal and temporal regions. Overall, the cortex was sig-
niﬁcantly thinner in 22q11DS+ Psychosis, with similar,
moderate effect sizes in the right and left hemispheres (d=
−0.63 and −0.58, respectively; see Supplementary Fig-
ures S5a, b for scatterplots of regional differences in CT and
SA). However, the overall classiﬁcation of the two groups
was not signiﬁcant (accuracy 61.2%, p= 0.19), when the
same Glmnet procedure detailed above was applied.
Pattern similarity in cortical measures between
22q11DS+ Psychosis and idiopathic schizophrenia
Effect sizes in Cohen’s d for regional CT deﬁcits in
22q11DS+ Psychosis versus 22q11DS-No-Psychosis were
D. Sun et al.
signiﬁcantly correlated with those in the ENIGMA idio-
pathic schizophrenia vs. control comparisons (r= 0.446,
p= 1.4 × 10−4). In contrast, the same effect sizes were not
correlated with those in the ENIGMA MDD vs. control
comparisons (r= 0.061, p= 0.619). Scatterplots for the
effect size correlations are shown in Fig. 3a,b.
Proximal nested (A–B) vs typical (A–D) deletions vs.
controls
After demographic matching, 23 22q11DS subjects with
A–B deletions, 108 subjects with A–D deletions, and 87
control subjects were compared using ANCOVA (see
demographics in Supplementary Tables S15a,b).
The anatomical patterns of CT and SA differences
between subjects with A–D deletions and controls (upper
panels of Fig. 4a,b) resembled those in the overall case-
control comparisons (Fig. 1).
Compared to healthy controls, subjects with A–B dele-
tions showed signiﬁcantly thinner cortex in the left anterior
superior temporal gyrus and right posterior cingulate gyrus,
and thicker cortex in bilateral pericalcarine and inferior
frontal regions (Fig. 4a, middle panel). Subjects with A–B
deletions also showed signiﬁcantly reduced SA in bilateral
medial occipital and cingulate cortex, as well as increased
SA in sensorimotor cortex (Fig. 4b, middle panel).
Relative to those with smaller (A–B) deletions, 22q11DS
subjects with A–D deletions showed highly signiﬁcant,
widespread reductions in cortical SA, most prominently in
the anterior portion of the medial cortical surface and
widely distributed lateral cortical regions (Fig. 4b, bottom
panel). No differences in CT between A–B and A–D
deletion cases surpassed FDR correction.
Scatterplots of regional differences in CT and SA
between 22q11DS subjects with A–B vs. A–D deletions and
vs. controls are shown in Supplementary Figures S6a,b,
respectively; t-values and signiﬁcance levels are presented
in Supplementary Tables S16a,b. These results are very
similar to the vertex-wise analysis results, indicating robust
effects of deletion size on regional cortical SA, most pro-
minently in frontal and parietal regions.
Medication, handedness and IQ effects on cortical
measures
Possible effects of medications on regional cortical mea-
sures in 22q11DS subjects were assessed using GLMs
(see Supplementary Methods). No signiﬁcant associations
were detected between psychotropic medications at the time
of MRI scan and either CT or SA (Supplementary
Table S17a,b) in any cortical regions. Analysis within the
22q11DS+ Psychosis group also showed minimal effects
of antipsychotic medication on cortical measuresTa
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(Table S18a,b). Similarly, effect sizes and signiﬁcance
levels for group differences were not substantively changed
by covarying handedness (Supplementary Table S19a,b).
Finally, patterns of group differences and signiﬁcance levels
largely remained unchanged when IQ was included a cov-
ariate, in overall case-control analyses (Supplementary
Figures S7a,b) and when comparing 22q11DS cases with
and without psychosis (Supplementary Figure S8).
Discussion
This study, the largest neuroimaging investigation ever
conducted of this well-characterized 22q11.2 deletion,
revealed several key ﬁndings. First, compared to healthy
controls, individuals with 22q11DS showed: (1) widespread
thicker cortex bilaterally (left/right hemisphere d= 0.614/
0.648), with the notable exception of thinner superior
temporal, cingulate, and parahippocampal cortex and (2)
widespread reductions in cortical SA; almost double the size
of the effects observed for CT (left/right hemisphere d=
−1.014/−1.021), with effects of greatest magnitude in
parieto-occipital regions and the anterior cingulate. Sec-
ondly, 22q11DS subjects with psychosis showed sig-
niﬁcantly thinner cortex relative to those without a history
of psychosis, with the strongest effects in fronto-temporal
regions that are also most prominently affected in idiopathic
psychosis [26, 47]. Finally, we found for the ﬁrst time that
Fig. 1 Vertex-Wise Mapping of Difference in CT and SA between
22q11DS and Healthy Control Subjects. a shows vertex-wise differ-
ences in CT, and b shows vertex-wise differences in SA. Colored areas
show p-values for group differences after FDR correction (q= 0.05)
for all vertices across both left and right cortical surfaces. Blue colors
represent signiﬁcant increases in 22q11DS subjects compared to
healthy controls, whereas red-yellow colors represent signiﬁcant
reductions in 22q11DS subjects. Compared to controls, subjects with
22q11DS showed greater CT and smaller SA, most prominently in the
posterior medial cortex including bilateral cuneus, precuneus, lingual
gyrus, pericalcarine cortex, and bilateral medial and lateral frontal
cortex. Subjects with 22q11DS showed a distinctive reduction of both
CT and SA in bilateral cingulate cortex. They also had reduced CT in
the superior temporal gyrus, and greater SA in the superior parietal
cortex and rostral middle frontal gyrus.
Fig. 2 Mapping of CT Differences between 22q11DS+ Psychosis and
22q11DS-No-Psychosis. Colored areas show p-values of group dif-
ference, and white circles include regions that pass FDR correction at
q= 0.05. Blue colors represent thicker cortical gray matter in
22q11DS+ Psychosis compared to 22q11DS-No-Psychosis, and red-
yellow colors represent thinner cortical gray matter in 22q11DS+
Psychosis vs. 22q11DS-No-Psychosis. Compared to those without
psychosis, 22q11DS subjects with psychosis showed signiﬁcantly
thinner cortex in the left superior temporal gyrus and lateral occipital
cortex, and right medial superior frontal, cingulate, pre- and post-
central, and supramarginal gyri
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larger deletion size was associated with signiﬁcantly
reduced cortical SA.
The prominent reductions in posterior SA we observed in
22q11DS cases overall may explain the previously observed
rostral-caudal gradient of volumetric deﬁcits [12]. Further,
the neuroanatomic signature of 22q11DS was so robust that
cases could be classiﬁed with high accuracy. Our ﬁndings
are consistent with imaging ﬁndings in the 22q11DS mouse
model, indicating differentially lower SA in posterior
brain regions with relative preservation of frontal regions
[48, 49].
To our knowledge, this is the largest-ever comparison of
demographically well-matched 22q11DS cases with and
without psychotic disorder. Findings of thinner fronto-
temporal cortex in 22q11DS+ Psychosis align well with
volumetric ﬁndings from prior, smaller studies [19, 28], but
the enhanced power of this multisite study revealed a more
extensive network of cortical regions. Effect sizes for the
signiﬁcant regional CT deﬁcits were in the medium range
(d= 0.45–0.70), similar to effect sizes for CT differences
between idiopathic schizophrenia cases and healthy controls
(d=−0.530/−0.516 for left/right hemisphere, respectively)
[47]. Indeed, our cross-diagnosis correlational analysis
indicated signiﬁcant convergence with brain regions pre-
dominantly affected in idiopathic schizophrenia, which is
supported by similar ﬁndings at the clinical phenotypic
level [50, 51]. Furthermore, the divergence with neuroana-
tomic effects of MDD indicates speciﬁcity of the brain
anatomic phenotype of 22q11DS+ Psychosis.
Our study also provides the ﬁrst evidence for phenotypic
differences as a function of deletion size. Prior, small stu-
dies found no detectable effect of deletion size on pheno-
typic severity [52–54], but these studies were likely
underpowered and, to our knowledge, none thus far inves-
tigated deletion size in relation to brain structure. Larger
A–D deletions were associated with substantially reduced
Fig. 3 Pattern similarity in CT deﬁcits between 22q11DS with psy-
chosis and idiopathic schizophrenia, in contrast to major depressive
disorder (MDD). Here we correlated the effect sizes (Cohen’s d) for
regional CT measures from the comparison between 22q11DS+
Psychosis and 22q11DS-No-Psychosis groups with those from the
ENIGMA Schizophrenia working group [47], in contrast to the
ENIGMA MDD study [35]. a Correlation in the effect sizes of CT
deﬁcits between idiopathic schizophrenia and 22q11+ Psychosis;
b Correlation in the effect sizes of CT deﬁcits between MDD and
22q11+ Psychosis. The effect sizes for CT deﬁcits from psychotic vs.
non-psychotic 22q11DS comparisons were signiﬁcantly correlated
with those in ENIGMA idiopathic schizophrenia vs. control compar-
isons. In contrast, the same effect sizes were not signiﬁcantly corre-
lated with those in ENIGMA MDD vs. control comparisons. Both x-
and y-axes represent effect sizes in Cohen’s d in the above-mentioned
comparison for all 68 cortical regions derived from the FreeSurfer
cortical parcellation. Abbreviations of the cortical regions are adopted
from the brainGraph package [67] as follows: BSTS banks of superior
temporal sulcus, cACC caudal anterior cingulate cortex, cMFG caudal
middle frontal gyrus, CUN cuneus, ENT entorhinal cortex, FUS fusi-
form gyrus, IPL inferior parietal cortex, ITG inferior temporal gyrus,
iCC isthmus cingulate cortex, LOG lateral occipital cortex, LOF lateral
orbitofrontal cortex, LING lingual gyrus, MOF medial orbitofrontal
cortex, MTG middle temporal gyrus, PARH parahippocampal gyrus,
paraC paracentral, lobule, pOPER pars opercularis of inferior frontal
gyrus, pORB pars orbitalis of inferior frontal gyrus, pTRI pars, trian-
gularis of inferior frontal gyrus, periCAL pericalcarine cortex, postC
post-central gyrus, PCC posterior, cingulate cortex, preC precentral
gyrus, PCUN precuneus, rACC rostral anterior cingulate corte, rMFG
rostral, middle frontal gyrus, SFG superior frontal gyrus, SPL superior
parietal cortex, STG superior temporal gyrus, SMAR supramarginal
gyrus, FP frontal pole, TP temporal pole, TT transverse temporal
gyrus, INS insula. L left, R right
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cortical SA, but not CT changes, compared to the smaller
A–B deletions, suggesting speciﬁc effects of deletion size
on cortical SA. Also of note, neuroanatomic differences
between individuals with A–B deletions and controls
showed a much narrower cortical distribution, restricted to
pericalcarine regions, relative to typical (A–D) 22q11DS
case vs. control differences.
Regarding developmental effects, we did not see much
evidence for divergent trajectories of cortical development
for 22q11DS cases overall, as few group x age interactions
Fig. 4 Vertex-wise mapping of differences in CT and SA, between A–B, A–D Deletion, and Control Subjects. For all ﬁgures, colored areas show
p-values of group difference that remain signiﬁcant after FDR correction (q= 0.05) for all vertices across both left and right cortical surfaces. The
positive and negative directions in the color-bars indicate the signs of differences after subtracting one group from another labelled on the left side.
a Differences in CT between A–B deletion, A–D deletion and control subjects. Compared to controls, subjects with A–B deletions showed thicker
cortex (in blue colors) in bilateral pericalcarine cortex and bilateral inferior frontal gyrus, and thinner cortex (in red-yellow colors) in the left
anterior superior temporal gyrus and right posterior cingulate cortex. Subjects with A–B deletions showed no signiﬁcant difference in CT in any
cortical region. The comparison of CT between subjects with A–D deletions and controls showed a similar pattern of group differences to the
overall 22q11DS case-control analysis (Fig. 1a), although effects were diminished. b Difference in SA between A–B deletion, A–D deletion, and
control subjects. Compared to controls, subjects with A–B deletions showed signiﬁcantly reduced SA (in red-yellow colors), more prominent in the
posterior portion of the medial and inferior cortical surface, including the bilateral cuneus, precuneus, pericalcarine, lingual, fusiform, and inferior
temporal regions, and caudal anterior cingulate. Increased SA in A–B deletion cases vs. controls was observed in bilateral precentral, paracentral,
and medial orbitofrontal regions (in blue colors). Compared to subjects with A–B deletions, subjects with A–D deletions showed widespread
signiﬁcant cortical SA reductions (in red-yellow colors), most prominently in the anterior portion of the medial cortical surface, including the
paracentral lobules, cingulate, precentral, superior frontal regions, and widely distributed lateral cortical regions. Like CT, the comparisons of SA
between subjects with A–D deletions and controls showed a similar pattern of group differences to the overall 22q11DS case-control analysis
(Fig. 1b), although effects were diminished
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were signiﬁcant. One prior longitudinal study observed
delayed prefrontal thinning over a three-year follow-up
period in adolescent patients with 22q11DS [55]. Given the
wide age range of our sample, with fewer participants at the
extreme ends of the age distribution, we may not have had
sufﬁcient power to detect interactions if they were present
primarily in these developmental periods. These questions
warrant further investigation in large, prospective long-
itudinal studies. In typical development, cortical thinning
begins between ages 2 to 4 years and continues across the
lifespan, whereas cortical SA follows a nonlinear matura-
tional trajectory beginning in fetal development [56, 57],
although it appeared largely linear within the age range
investigated here. Increased progenitor cell production
during embryonic development predominantly inﬂuences
expansion of SA [58–61]; in contrast, CT depends on the
neuronal output from each radial unit, and is thus con-
sidered a proxy for the number of cells in a column [58, 60].
As such, the observed pervasive SA decreases in 22q11DS
may reﬂect reduced progenitor cell production in multiple
cortical regions, implying that this distinctive phenotype in
22q11DS originates early in the course of brain
development.
Currently, the precise genetic mechanisms underlying
disrupted cortical circuit formation, and the dramatically
elevated risk for psychosis in 22q11DS are unknown. Most
of the protein-coding genes within the region are highly
brain-expressed [62], with several involved in early neuro-
development. Some of these (e.g., RANBP1, CDC45L) are
selectively expressed in cortical progenitors in the ven-
tricular/subventricular zones, whereas others (e.g., DGCR8,
involved in microRNA biogenesis) are more broadly
expressed in cortical neurons [63]. As RANBP1 plays a role
in rapidly dividing precursors in the developing brain,
hemizygosity of this gene may lead to a reduction in the
overall pool of cortical radial glial progenitors [64], and
thus smaller cortical area. 22q11DS mouse models show
widespread deﬁcits in dendritic complexity and spine den-
sity, altered synaptic plasticity, and reduced hippocampal-
prefrontal synchrony, changes that correlates with working
memory impairments [65]. However, further studies are
needed to isolate the precise genes responsible for the ele-
vated psychosis risk and pattern of neuroanatomic
abnormalities observed here.
One key advantage of this study is that we were able to
conduct all analyses on raw data, ensuring consistent data
processing and allowing vertex-wise analyses, results of
which were highly consistent with ROI analyses. Some
limitations, however, must be noted. The cross-site varia-
bility in age, stage of the disease, incidence of psychosis,
and distribution of deletion types potentially confounded
cortical measures. For this reason, we matched site/data set,
sex, and age in several comparisons to address this
variability. Given that only ~10% of 22q11.2 deletions
overall are of the A–B type [2], this group is necessarily
small; although effect sizes for SA differences were large,
these ﬁndings nevertheless warrant replication in indepen-
dent samples. Further, some 22q11DS subjects without
psychosis in the current analyses might develop symptoms
at a later point, so their inclusion in the non-psychotic group
would likely have attenuated real group differences. Also,
investigation of the neuroanatomic effects of other common
associated comorbidities of 22q11DS (e.g., cardiac defects,
autism spectrum disorders) was outside the scope of this
study, but should be pursued in follow-up studies in simi-
larly sized samples.
This genetically-deﬁned neurodevelopmental condition
offers a biologically tractable framework to dissect genetic
mechanisms underlying brain phenotypes associated with
complex neuropsychiatric disorders. Importantly, the brain
phenotype of 22q11DS+ Psychosis is substantially shared
with idiopathic schizophrenia, suggesting that genetic sub-
types of psychosis can provide insights into brain
mechanisms associated with psychosis more broadly. Cur-
rently, a large-scale whole genome sequencing study
(International 22q11.2 Brain-Behavior Consortium; IBBC)
[44] is underway to investigate both rare and common
variants that may contribute to psychosis risk in these
patients [66]. This large-scale ‘genetics ﬁrst’ approach, in
combination with translational studies in animal and in vitro
models, is likely to yield novel insights into the elusive
molecular biology of psychosis.
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